Orlistat-Associated Adverse Effects and Drug Interactions

[1]  S. Konitsiotis,et al.  Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study. , 2008, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[2]  E. Liberopoulos,et al.  The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. , 2007, Atherosclerosis.

[3]  S. Majumdar,et al.  Drug treatments for obesity: orlistat, sibutramine, and rimonabant , 2007, The Lancet.

[4]  A. Burroughs,et al.  Pharmacological treatment of non-alcoholic steatohepatitis: The current evidence , 2007, Scandinavian journal of gastroenterology.

[5]  S. Toubro,et al.  Effect of Orlistat on Weight Regain and Cardiovascular Risk Factors Following a Very-Low-Energy Diet in Abdominally Obese Patients , 2007, Diabetes Care.

[6]  A. Courtney,et al.  Rapidly progressive renal failure associated with successful pharmacotherapy for obesity. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  E. Diamanti-Kandarakis,et al.  Effect of long‐term orlistat treatment on serum levels of advanced glycation end‐products in women with polycystic ovary syndrome , 2006, Clinical endocrinology.

[8]  M. Perazella,et al.  Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  B. Beermann,et al.  Incorrect use of orlistat and sibutramine in clinical practice , 2007, European Journal of Clinical Pharmacology.

[10]  C. McGuigan,et al.  Reduced absorption of lipophilic anti-epileptic medications when used concomitantly with the anti-obesity drug orlistat. , 2006, Epilepsia.

[11]  J. Menéndez,et al.  Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? , 2006, Current pharmaceutical biotechnology.

[12]  Reawika Chaikomin,et al.  Effects of lipase inhibition on gastric emptying and alcohol absorption in healthy subjects , 2006, British Journal of Nutrition.

[13]  L. Wilton,et al.  Safety profile of orlistat: results of a prescription-event monitoring study , 2006, International Journal of Obesity.

[14]  Jeffrey W. Smith,et al.  Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report , 2006, BMC psychiatry.

[16]  S. B. Garcia,et al.  The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen. , 2006, Cancer letters.

[17]  Matthew Thomas,et al.  36 year old man presenting with pancreatitis and a history of recent commencement of orlistat case report , 2006, Nutrition journal.

[18]  T. Umemura,et al.  Severe hepatic injury caused by orlistat. , 2006, The American journal of medicine.

[19]  M. Hsieh,et al.  Effect of orlistat in overweight poorly controlled Chinese female type 2 diabetic patients: a randomised, double‐blind, placebo‐controlled study , 2006, International journal of clinical practice.

[20]  A. Więcek,et al.  The influence of a 3-month weight reduction therapy with Orlistat on serum vitamin B12 and folic acid concentration in obese women , 2006, International Journal of Obesity.

[21]  D. Mikhailidis,et al.  Leptin: a promising therapeutic target with pleiotropic action besides body weight regulation. , 2006, Current drug targets.

[22]  A. Sergeant,et al.  Lichenoid eruption associated with orlistat , 2006, The British journal of dermatology.

[23]  M. Leshno,et al.  Double-Blind Randomized Placebo-Controlled Trial of Orlistat or the Treatment of Nonalcoholic Fatty Liver Disease , 2022 .

[24]  A. Burroughs,et al.  Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study , 2006, Current medical research and opinion.

[25]  E. Diamanti-Kandarakis,et al.  Short-term effect of orlistat on dietary glycotoxins in healthy women and women with polycystic ovary syndrome. , 2006, Metabolism: clinical and experimental.

[26]  M. Bertolami,et al.  Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study. , 2006, Arquivos brasileiros de endocrinologia e metabologia.

[27]  E. Liberopoulos,et al.  Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. , 2006, Current drug targets.

[28]  J. Menéndez,et al.  The antiobesity drug Orlistat induces cytotoxic effects, suppresses Her-2/neu (erbB-2) oncogene overexpression, and synergistically interacts with trastuzumab (Herceptin) in chemoresistant ovarian cancer cells. , 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[29]  E. Taskin,et al.  Effects of orlistat and its relationship with nitric oxide in the small intestinal mucosa. , 2005, The Chinese journal of physiology.

[30]  W. Syn,et al.  Orlistat (Xenical)-induced subacute liver failure. , 2005, European journal of gastroenterology & hepatology.

[31]  D. Mikhailidis,et al.  Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study , 2005, Current medical research and opinion.

[32]  Z. Pavlovic.  Orlistat in the treatment of clozapine-induced hyperglycemia and weight gain , 2005, European Psychiatry.

[33]  L. V. Van Gaal,et al.  X‐PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced‐energy diet. Early response to treatment predicts weight maintenance , 2005, Diabetes, obesity & metabolism.

[34]  P. McEwan,et al.  The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss , 2005, Current medical research and opinion.

[35]  A. Golay,et al.  Effect of orlistat in obese patients with binge eating disorder. , 2005, Obesity research.

[36]  S. Oren,et al.  Effect of Weight Loss on Blood Pressure, Arterial Compliance, and Insulin Resistance in Normotensive Obese Subjects , 2005, The American journal of the medical sciences.

[37]  A. Hartley,et al.  Hypothyroidism in thyroid carcinoma follow-up: orlistat may inhibit the absorption of thyroxine. , 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

[38]  M. Fox,et al.  The Effects of Loperamide on Continence Problems and Anorectal Function in Obese Subjects Taking Orlistat , 2005, Digestive Diseases and Sciences.

[39]  J. Menéndez,et al.  Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  A. Guarino.  Treatment of intractable constipation with orlistat: a report of three cases. , 2005, Pain medicine.

[41]  M. Hsieh,et al.  Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double‐blind, placebo‐controlled study , 2005, International journal of clinical practice.

[42]  M. Boldrin,et al.  Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. , 2005, JAMA.

[43]  C. Berne.  A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[44]  J. Menéndez,et al.  Orlistat: From Antiobesity Drug to Anticancer Agent in Her-2/neu (erbB-2)-Overexpressing Gastrointestinal Tumors? , 2005, Experimental biology and medicine.

[45]  E. Liberopoulos,et al.  A review of the metabolic effects of sibutramine , 2005, Current medical research and opinion.

[46]  S. Atkin,et al.  Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. , 2005, The Journal of clinical endocrinology and metabolism.

[47]  M. Elisaf,et al.  The effects of orlistat on metabolic parameters and other cardiovascular risk factors. , 2005, Diabetes & metabolism.

[48]  R. Fogari,et al.  Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients , 2005, Diabetes, obesity & metabolism.

[49]  M. Fried,et al.  Influence of orlistat on the regulation of gallbladder contraction in man , 1996, Digestive Diseases and Sciences.

[50]  J. Wishart,et al.  Effects of lipase inhibition on gastric emptying of, and on the glycaemic, insulin and cardiovascular responses to, a high-fat/carbohydrate meal in type 2 diabetes , 2004, Diabetologia.

[51]  C. Ekmekcioglu,et al.  Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. , 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[52]  A. Więcek,et al.  [Effect of orlistat therapy on carbohydrate, lipid, vitamin and hormone plasma levels in obese subjects]. , 2004, Polskie Archiwum Medycyny Wewnetrznej.

[53]  D. Helinski,et al.  A pilot study of orlistat treatment in obese, non‐alcoholic steatohepatitis patients , 2004, Alimentary pharmacology & therapeutics.

[54]  R. Fogari,et al.  Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. , 2004, Diabetes, nutrition & metabolism.

[55]  H. Tiselius,et al.  Fat malabsorption induced by gastrointestinal lipase inhibitor leads to an increase in urinary oxalate excretion. , 2004, Kidney international.

[56]  E. Coban,et al.  Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women , 2004, International Journal of Obesity.

[57]  A. Thanopoulou,et al.  The ORlistat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORliCARDIA) study , 2004, Current medical research and opinion.

[58]  Z. Oşar,et al.  Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients. , 2004, Diabetes care.

[59]  Z. Latif,et al.  Orlistat as an adjunct therapy in type 2 obese diabetic patients treated with sulphonylurea: a Bangladesh experience. , 2004, Bangladesh Medical Research Council bulletin.

[60]  Jeffrey W. Smith,et al.  Orlistat Is a Novel Inhibitor of Fatty Acid Synthase with Antitumor Activity , 2004, Cancer Research.

[61]  M. Fox,et al.  The pathophysiology of faecal spotting in obese subjects during treatment with orlistat , 2004, Alimentary pharmacology & therapeutics.

[62]  S. O’Meara,et al.  A systematic review of the clinical effectiveness of orlistat used for the management of obesity , 2004, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[63]  M K Campbell,et al.  Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. , 2004, Health technology assessment.

[64]  L. Sjöström,et al.  XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. , 2004, Diabetes care.

[65]  E. Lambert,et al.  Effects of a lipase inhibitor (Orlistat) on cholecystokinin and appetite in response to a high-fat meal , 2003, International Journal of Obesity.

[66]  D. Lau,et al.  Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials , 2003, International Journal of Obesity.

[67]  E. Muxfeldt,et al.  Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial , 2003, Journal of hypertension.

[68]  J. Zhi,et al.  The Effect of Short-Term (21-Day) Orlistat Treatment on the Physiologic Balance of Six Selected Macrominerals and Microminerals in Obese Adolescents , 2003, Journal of the American College of Nutrition.

[69]  J. Meyer,et al.  Effect of lipase inhibition on gastric emptying of, and the glycemic and incretin responses to, an oil/aqueous drink in type 2 diabetes mellitus. , 2003, The Journal of clinical endocrinology and metabolism.

[70]  A. Rissanen,et al.  Lowering of LDL cholesterol rather than moderate weight loss improves endothelium-dependent vasodilatation in obese women with previous gestational diabetes. , 2003, Diabetes care.

[71]  A. Halpern,et al.  Latin‐American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients , 2003, Diabetes, obesity & metabolism.

[72]  J. Zhi,et al.  Effects of Orlistat, a Lipase Inhibitor, on the Pharmacokinetics of Three Highly Lipophilic Drugs (Amiodarone, Fluoxetine, and Simvastatin) in Healthy Volunteers , 2003, Journal of clinical pharmacology.

[73]  R. Macwalter,et al.  Orlistat Enhances Warfarin Effect , 2003, The Annals of pharmacotherapy.

[74]  R. Fogari,et al.  Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. , 2003, Clinical therapeutics.

[75]  D. Goldsmith,et al.  Drug interaction in a renal transplant patient: cyclosporin-Neoral and orlistat. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[76]  R. Ozaki,et al.  The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes. , 2002, Archives of internal medicine.

[77]  G. Bakris,et al.  Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension , 2002, Journal of hypertension.

[78]  M. Hanefeld,et al.  The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo‐controlled trial , 2002, Diabetes, obesity & metabolism.

[79]  M. González‐Gay,et al.  Orlistat-induced cutaneous leukocytoclastic vasculitis. , 2002, Arthritis and rheumatism.

[80]  G. Lau,et al.  Massive hepatocellular [correction of hepatocullular] necrosis: was it caused by Orlistat? , 2002, Medicine, science, and the law.

[81]  S. Patten.  Major depressive episodes and diet pills , 2002, Expert opinion on pharmacotherapy.

[82]  L. Aronne,et al.  Erratum: Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin (Diabetes Care (2002) 25 (1123-1128)) , 2002 .

[83]  J. Hwang,et al.  [A case of acute cholestatic hepatitis associated with Orlistat]. , 2002, Taehan Kan Hakhoe chi = The Korean journal of hepatology.

[84]  J. Zhi,et al.  Pharmacokinetic Evaluation of the Possible Interaction between Selected Concomitant Medications and Orlistat at Steady State in Healthy Subjects , 2002, Journal of clinical pharmacology.

[85]  Arya M. Sharma,et al.  Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension , 2002, Journal of hypertension.

[86]  J. Wilding,et al.  RANDOMISED TRIAL OF THE EFFECT OF ORLISTAT ON BODY WEIGHT AND CARDIOVASCULAR DISEASE RISK PROFILE IN OBESE PATIENTS: UK MULTIMORBIDITY STUDY , 2002, International journal of clinical practice.

[87]  R. Wurdeman,et al.  Constipation, Polyuria, Polydipsia, and Edema Associated with Orlistat , 2002, The Annals of pharmacotherapy.

[88]  S. Booth,et al.  Effects of Orlistat on Fat‐Soluble Vitamins in Obese Adolescents , 2002, Pharmacotherapy.

[89]  L. Aronne,et al.  Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. , 2002, Diabetes care.

[90]  A. Heck,et al.  Additive Gastrointestinal Effects with Concomitant Use of Olestra and Orlistat , 2002, The Annals of pharmacotherapy.

[91]  F Xavier Pi-Sunyer,et al.  Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. , 2002, Diabetes care.

[92]  S. Pallini,et al.  Obesity in transplant patients: case report showing interference of orlistat with absorption of cyclosporine and review of literature. , 2002, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[93]  E. Hilger,et al.  The Effect of Orlistat on Plasma Levels of Psychotropic Drugs in Patients With Long-term Psychopharmacotherapy , 2002, Journal of clinical psychopharmacology.

[94]  I. García,et al.  Reduction in blood cyclosporine concentration by orlistat in two renal transplant patients. , 2002, Transplantation proceedings.

[95]  F. Fernández-Aranda,et al.  Bulimia nervosa and misuse of orlistat: two case reports. , 2001, The International journal of eating disorders.

[96]  L. Kopelovich,et al.  A Western-style diet induces benign and malignant neoplasms in the colon of normal C57Bl/6 mice. , 2001, Carcinogenesis.

[97]  T. Andersen,et al.  Influence of orlistat on bone turnover and body composition , 2001, International Journal of Obesity.

[98]  G. Medeiros-Neto,et al.  Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid) , 2001, International Journal of Obesity.

[99]  P. Hadváry,et al.  Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[100]  G. Deuschl,et al.  The pathophysiology of tremor , 2001, Muscle & nerve.

[101]  R. Guerciolini,et al.  Short-term orlistat treatment does not affect mineral balance and bone turnover in obese men. , 2001, The Journal of nutrition.

[102]  G. Reaven,et al.  Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. , 2001, The American journal of cardiology.

[103]  S. Azar,et al.  Diabetic ketoacidosis associated with orlistat treatment. , 2001, Diabetes care.

[104]  G. D. Johnston.  Orlistat associated with hypertension , 2001, BMJ : British Medical Journal.

[105]  Huber Mh.  Orlistat associated with hypertension. Roche concludes that there is not evidence of a casual association. , 2001 .

[106]  J. Muntané,et al.  Orlistat associated subacute hepatic failure. , 2001, Journal of hepatology.

[107]  S. O’Meara,et al.  A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. , 2001, Health technology assessment.

[108]  P. Whiting,et al.  A rapid and systematic review of the clinical effectiveness and cost-effectiveness of debriding agents in treating surgical wounds healing by secondary intention. , 2001, Health technology assessment.

[109]  B. Faidutti,et al.  Orlistat decreases the plasma level of cyclosporine and may be responsible for the development of acute rejection episodes. , 2000, Transplantation.

[110]  R. Guillemain,et al.  Co-administration of orlistat and cyclosporine in a heart transplant recipient. , 2000, Transplantation.

[111]  R. Peleg.  Caution when using oral contraceptive pills with Orlistat. , 2000, The Israel Medical Association journal : IMAJ.

[112]  S. Vitols,et al.  Orlistat associated with hypertension , 2000, BMJ : British Medical Journal.

[113]  G. Rn.  The effect of managed care on medical education. , 2000 .

[114]  E. Rüther,et al.  Electroconvulsive therapy and anticoagulation. , 2000, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[115]  H. Nägele,et al.  Effect of orlistat on blood cyclosporin concentration in an obese heart transplant patient , 1999, European Journal of Clinical Pharmacology.

[116]  S. Heymsfield,et al.  Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. , 1999, JAMA.

[117]  J. Zhi,et al.  Long‐Term Systemic Exposure of Orlistat, a Lipase Inhibitor, and Its Metabolites in Obese Patients , 1999, Journal of clinical pharmacology.

[118]  J. Zavoral.  Treatment with orlistat reduces cardiovascular risk in obese patients , 1998, Journal of hypertension.

[119]  Roy A Kaplan,et al.  Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study , 1998, Diabetes Care.

[120]  Alain Golay,et al.  Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients , 1998, The Lancet.

[121]  L. V. Van Gaal,et al.  Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study , 1998, European Journal of Clinical Pharmacology.

[122]  J. Zhi,et al.  The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers , 1998, European Journal of Clinical Pharmacology.

[123]  R. Guerciolini.  Mode of action of orlistat. , 1997, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[124]  M. Onoue,et al.  Effects of a high-fat diet on azoxymethane-induced aberrant crypt foci and fecal biochemistry and microbial activity in rats. , 1997, Nutrition and cancer.

[125]  R. Macdonald,et al.  Dietary fat quantity and composition induce changes in proliferation and membrane lipids in rat colon cells. , 1997, Annals of nutrition & metabolism.

[126]  J. Zhi,et al.  Metabolic Profiles of Minimally Absorbed Orlistat in Obese/Overweight Volunteers , 1996, Journal of clinical pharmacology.

[127]  J. Zhi,et al.  The Effect of Orlistat, an Inhibitor of Dietary Fat Absorption, on the Absorption of Vitamins A and E in Healthy Volunteers , 1996, Journal of clinical pharmacology.

[128]  J. Zhi,et al.  The Effect of Orlistat on the Pharmacokinetics of Phenytoin in Healthy Volunteers , 1996, Journal of clinical pharmacology.

[129]  S. Passe,et al.  The Effect of Orlistat on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Volunteers , 1996, Journal of clinical pharmacology.

[130]  J. Wark,et al.  Bone loss accompanying diet-induced or exercise-induced weight loss: a randomised controlled study. , 1996, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[131]  J. Zhi,et al.  Lack of Effect of Orlistat on the Bioavailability of a Single Dose of Nifedipine Extended‐Release Tablets (Procardia XL) in Healthy Volunteers , 1996, Journal of clinical pharmacology.

[132]  J. Zhi,et al.  The Effect of Orlistat, an Inhibitor of Dietary Fat Absorption, on the Pharmacokinetics of β‐Carotene in Healthy Volunteers , 1996, Journal of clinical pharmacology.

[133]  Y. Tam,et al.  Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers , 1996, European Journal of Clinical Pharmacology.

[134]  D. Hartmann,et al.  Lack of interaction between orlistat and oral contraceptives , 1996, European Journal of Clinical Pharmacology.

[135]  J. Zhi,et al.  Review of Limited Systemic Absorption of Orlistat, a Lipase Inhibitor, in Healthy Human Volunteers , 1995, Journal of clinical pharmacology.

[136]  J. Zhi,et al.  The Influence of Orlistat on the Pharmacokinetics and Pharmacodynamics of Glyburide in Healthy Volunteers , 1995, Journal of clinical pharmacology.

[137]  J. Zhi,et al.  Retrospective population‐based analysis of the dose‐response (fecal fat excretion) relationship of orlistat in normal and obese volunteers , 1994, Clinical pharmacology and therapeutics.